Ceramide nanoliposomes as a novel therapeutic option for lethal prostate cancer: exploiting DE novo sphingolipid synthesis

Ended Project Grant Awarded Last action

Award ID
W81XWH2210696
Recipient
Awarding agency
Obligated
$2,256,672

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Funding
  • $1,128,336.00 Federal
  • $1,128,336.00 Non-federal
Place of performance
Charlottesville, VA, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

This Project Grant award from the Department of the Army Medical Command provides $2,256,672 to the University of Virginia to support research into novel therapeutic options for lethal prostate cancer. The funding period is from August 1, 2022 to July 31, 2025.

The award is part of the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve health care for service members and the public. Specifically, the University of Virginia will investigate ceramide nanoliposomes as a potential treatment for castration-resistant prostate cancer. If successful, this research could lead to new therapeutic approaches that increase treatment options for patients.

The grant includes subawards to support various tasks. The Henry M. Jackson Foundation for the Advancement of Military Medicine will assist with understanding the regulation of de novo sphingolipid synthesis. The University of Maryland, Baltimore and Dana-Farber Cancer Institute will provide additional expertise to determine the transcriptional and epigenetic factors involved in prostate cancer pathogenesis and evaluate the translational potential of ceramide nanoliposomes in preclinical models.

Subawards

Subrecipient Amount Awarded
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Specific Aim 1: Determine the regulatory and transcriptional mechanism by which AR regulates SPTSSB and de novo ceramide synthesis in PCa. Specific Aim 2:… $35,101
Dana-Farber Cancer Institute, Inc. Dr. Pomerantz will work with the study team at UVA to provide analysis and expertise related to: Prostate cancer (PCa) accounted for ~20% of the new cancer… $16,967
University Of Maryland, Baltimore Prostate cancer (PCa) accounted for ~20% of the new cancer cases in men in the US during 2020, the second highest. Androgen Receptors (AR) has been the main… $6,988
University Of Maryland, Baltimore Statement of Work Prostate cancer (PCa) accounted for ~20% of the new cancer cases in men in the US during 2020, the second highest. Androgen Receptors (AR) has… $6,988
Dana-Farber Cancer Institute, Inc. Dr. Pomerantz will work with the study at UVA to provide analysis and expertise related to: Prostate cancer (PCa) accounted for ~20% of the new cancer cases… $16,474

Quick answers

Who received award W81XWH2210696?

W81XWH2210696 was awarded to Rector & Visitors Of The University Of Virginia by Medical Command (Department of the Army) on August 1, 2022.

How much is award W81XWH2210696 worth?

$2,256,672 has been obligated on W81XWH2210696: $1,128,336 in federal funding and $1,128,336 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login